Results 11 to 20 of about 70,663 (209)

Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation. [PDF]

Int J Mol Sci
Genetically modified T lymphocytes expressing chimeric antigen receptors (CARs) are becoming increasingly important in the treatment of hematologic malignancies and are also intensively being investigated for other diseases such as autoimmune disorders and HIV.
Kitte R, Serfling R, Blache U, Seitz C, Schrader S, Köhl U, Fricke S, Bär C, Tretbar US.   +8 more
europepmc   +3 more sources

Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies. [PDF]

Cancer Cell Int
Cancer immunotherapy has reshaped the landscape of cancer treatment over the past decades. Genetic manipulation of T cells to express synthetic receptors, known as chimeric antigen receptors (CAR), has led to the creation of tremendous commercial and therapeutic success for the treatment of certain hematologic malignancies.
Nasiri F, Safarzadeh Kozani P, Salem F, Mahboubi Kancha M, Dashti Shokoohi S, Safarzadeh Kozani P.   +5 more
europepmc   +5 more sources

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma. [PDF]

Pathog Immun
This review focuses on the use of chimeric antigen receptor (CAR)-T cell therapy to treat non-Hodgkin’s lymphoma (NHL), a classification of heterogeneous malignant neoplasms of the lymphoid tissue. Despite various conventional and multidrug chemotherapies, the poor prognosis for NHL patients remains and has prompted the utilization of groundbreaking ...
Giraudo MF, Jackson Z, Das I, Abiona OM, Wald DN.   +4 more
europepmc   +4 more sources

Chimeric Antigen Receptor beyond CAR-T Cells [PDF]

Cancers, 2021
Chimeric antigen receptors (CAR) are genetically engineered receptors that can recognise specific antigens and subsequently activate downstream signalling. Human T cells engineered to express a CAR, also known as CAR-T cells, can target a specific tumour antigen on the cell surface to mediate a cytotoxic response against the tumour.
Vicky Mengfei Qin, Criselle D’Souza, Paul J. Neeson, Joe Jiang Zhu   +3 more
openaire   +3 more sources

Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological cancers and is currently being investigated for solid tumours, including high-grade glioma brain tumours.
Abler, Daniel, Adhikarla, Vikram, Barish, Michael, Branciamore, Sergio, Brown, Christine E, Cho, Heyrim, Frankhouser, David, Gutova, Margarita, Machuca, Vanessa, Maestrini, Davide, Rockne, Russell C, Sahoo, Prativa, Wang, Dongrui, Yang, Xin   +13 more
core   +2 more sources

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)

Mediterranean Journal of Hematology and Infectious Diseases, 2021
Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-T to treat multiple myeloma and other hematological malignancies.
Galli, Eugenio, Bellesi, Silvia, Viscovo, Marcello, Sora, Federica, Hohaus, Stefan, Piccirillo, Nicola, Laurenti, Luca, Chiusolo, Patrizia, De Stefano, Valerio, Sica, Simona, Zini, Gina   +10 more
openaire   +6 more sources

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy [PDF]

Expert Opinion on Biological Therapy, 2011
Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from MHC restriction and thus breaking one of the barriers to more widespread application of cellular therapy.
Carlos A, Ramos, Gianpietro, Dotti
openaire   +2 more sources

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. [PDF]

, 2020
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response.
Chari, Ajai, Mezzi, Khalid, Scott, Emma, Shah, Nina, Usmani, Saad Z   +4 more
core   +1 more source

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells [PDF]

International Journal of Molecular Sciences, 2019
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen receptor (CAR) T cell therapy. CAR T cells mediate MHC-unrestricted tumor cell killing by enabling T cells to bind target cell surface antigens through a single-chain ...
Mohamed-Reda Benmebarek, Clara Helke Karches, Bruno Loureiro Cadilha, Stefanie Lesch, Stefan Endres, Sebastian Kobold   +5 more
openaire   +2 more sources

Chimeric Antigen Receptor (CAR) therapy for multiple myeloma [PDF]

British Journal of Haematology, 2016
SummaryThe introduction of chimeric antigen receptor (CAR)‐modified T cells has revolutionized immunotherapy and cancer treatment as a whole. However, so far, clinical efficacy has only been demonstrated for CD19‐positive B cell lymphomas. For Multiple Myeloma (MM), the second most common haematological malignancy, there are currently no clinical ...
Djordje, Atanackovic, Sabarinath V, Radhakrishnan, Neelam, Bhardwaj, Tim, Luetkens   +3 more
openaire   +2 more sources